Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Expanding Novel Treatment Options for Patients With T-Cell ALL

February 2nd 2023

A brief review of T-Cell acute lymphoblastic leukemia and emerging novel therapies that may improve upon its existent treatment armamentarium.

Unmet Needs and Future Directions in the Management of Myelofibrosis

February 2nd 2023

Naveen Pemmaraju, MD, highlights unmet needs in the setting of myelofibrosis management and looks toward future evolutions in the treatment paradigm.

Interpreting Data From the REFINE Study: Ruxolitinib + Navitoclax in Myelofibrosis

February 2nd 2023

Expert perspectives on specific subsets of the REFINE study, which combined ruxolitinib with navitoclax in patients diagnosed with myelofibrosis.

Case 1 Presentation: Lower-Risk MDS with Multiple Chromosomal Abnormalities

February 2nd 2023

Guillermo Garcia-Manero, MD presents a case of lower-risk MDS with chromosome 5q and 20q deletions and a p53 mutation, and discusses first- and second-line treatment selection.

Disease Modification in Myelofibrosis: The Current Treatment Paradigm

February 2nd 2023

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

Overview on Myelofibrosis: Diagnosis, Staging, and Molecular Testing

February 2nd 2023

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

Myeloproliferative Neoplasm Management: Future Directions in Care

February 2nd 2023

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Second-Line Treatment Options for Lower-Risk MDS

February 2nd 2023

Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.

Data on Emerging Therapies for Treatment of Higher-Risk MDS

February 1st 2023

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.

Oral Hypomethylating Agents in MDS: Data Updates

February 1st 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, discuss trial updates on oral hypomethylating agents, including data on dosing, for treatment of lower-risk MDS.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Taking a Closer Look at Cilta-cel and CARTITUDE-1 Data

February 1st 2023

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

Remestemcel-L BLA Resubmitted to FDA for Pediatric Steroid-Refractory aGVHD

February 1st 2023

A biologics license application seeking the approval of remestemcel-L has been resubmitted to the FDA for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

Brentuximab Vedotin Plus Nivolumab/Dacarbazine/Doxorubicin Produces Promising Efficacy in Hodgkin Lymphoma

January 31st 2023

Mitul Gandhi, MD, discusses the rationale of combining brentuximab vedotin, nivolumab, dacarbazine, and doxorubicin for patients with early-stage classic Hodgkin lymphoma, the key findings from part C of the SGN35-027 trial, and the next steps for investigating this combination.

Tumor Lysis Syndrome: Clinical Implications of Prophylaxis and Treatment

January 31st 2023

Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.

Acute Myeloid Leukemia: Optimizing Risk Stratification

January 31st 2023

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

Molecular Biomarker Testing in Acute Myeloid Leukemia

January 31st 2023

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

Guideline-Directed Treatment Options for Tumor Lysis Syndrome

January 31st 2023

James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.

NICE Recommends Axicabtagene Ciloleucel for Lymphoma

January 30th 2023

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of axicabtagene ciloleucel for adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma following at least 2 previous lines of systemic therapy.

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

The combination of magrolimab, rituximab, gemcitabine, and oxaliplatin produced deep, durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of luspatercept for the treatment of patients with anemia associated with non–transfusion dependent beta thalassemia.